The Manufacturers Life Insurance Company lifted its stake in shares of Liquidia Co. (NASDAQ:LQDA – Free Report) by 25.2% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 22,706 shares of the company’s stock after purchasing an additional 4,572 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Liquidia were worth $272,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Squarepoint Ops LLC boosted its stake in Liquidia by 53.4% in the second quarter. Squarepoint Ops LLC now owns 82,272 shares of the company’s stock valued at $987,000 after buying an additional 28,638 shares in the last quarter. Marshall Wace LLP acquired a new stake in Liquidia in the second quarter valued at about $545,000. HighVista Strategies LLC acquired a new stake in Liquidia in the second quarter valued at about $1,461,000. Profund Advisors LLC boosted its stake in Liquidia by 31.6% in the second quarter. Profund Advisors LLC now owns 14,434 shares of the company’s stock valued at $173,000 after buying an additional 3,466 shares in the last quarter. Finally, Quest Partners LLC acquired a new stake in Liquidia in the second quarter valued at about $27,000. 64.54% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, Director Caligan Partners Lp acquired 150,000 shares of the firm’s stock in a transaction dated Friday, August 30th. The stock was purchased at an average price of $9.51 per share, for a total transaction of $1,426,500.00. Following the completion of the acquisition, the director now directly owns 6,994,997 shares in the company, valued at $66,522,421.47. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, insider Rajeev Saggar sold 2,260 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $25,108.60. Following the completion of the sale, the insider now owns 207,383 shares in the company, valued at approximately $2,304,025.13. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Caligan Partners Lp purchased 150,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were bought at an average price of $9.51 per share, with a total value of $1,426,500.00. Following the acquisition, the director now directly owns 6,994,997 shares of the company’s stock, valued at $66,522,421.47. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 20,858 shares of company stock worth $228,724 over the last quarter. 31.60% of the stock is currently owned by corporate insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Liquidia
Liquidia Stock Performance
Shares of LQDA opened at $11.14 on Friday. Liquidia Co. has a 52-week low of $5.71 and a 52-week high of $16.99. The business’s 50 day moving average price is $10.41 and its two-hundred day moving average price is $11.94. The firm has a market cap of $851.25 million, a PE ratio of -7.14 and a beta of 0.22.
Liquidia (NASDAQ:LQDA – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative net margin of 755.46% and a negative return on equity of 183.57%. The business had revenue of $3.66 million during the quarter, compared to analyst estimates of $7.92 million. Research analysts predict that Liquidia Co. will post -1.69 EPS for the current fiscal year.
Liquidia Company Profile
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
See Also
- Five stocks we like better than Liquidia
- How Technical Indicators Can Help You Find Oversold Stocks
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Upcoming IPO Stock Lockup Period, Explained
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.